Attila A. Seyhan, Ph.D. is the Director of Translational Oncology Operations at Cancer Center at Brown University, the Joint Program in Cancer Biology, Brown University and Lifespan Health System, Warren Alpert Medical School, Brown University.
He is also an Adjunct Associate Professor (Research), Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, Providence, RI.
He manages and promotes multiple initiatives, including the development of investigator-initiated clinical trials and other translational protocols, protocol writing and manuscript preparation, organization of translational medicine events, support for translational requests for application (RFAs), and grant preparation and submissions.
He also works with industry to follow through on investigator-initiated basic and translational letters of intent (LOIs) and concepts. This work will involve collaboration with clinicians, scientists, regulatory personnel, administrators, tech transfer office staff, the grants management office, institutional review board (IRB), institutional advancement, and external entities.
His most recent position was Director of Translational Medicine Operations, Associate Research Professor, Translational Medicine, Fox Chase Cancer Center / Temple University.
Previously, he was Associate Professor at the Translational Research Institute for Metabolism and Diabetes at Florida Hospital in Orlando, FL, and Adjunct Associate Professor at Sanford Burnham Prebys Medical Discovery Institute, in Orlando (Lake Nona), FL. In addition, he served as a research affiliate in the Department of Chemical Engineering at the Massachusetts Institute of Technology in Boston, MA.
In addition to academia, Dr. Seyhan has spent significant time in the pharmaceutical and biotechnology industries, having served in leading roles as Senior Principal Scientist at Pfizer Pharmaceuticals in Cambridge, MA., Principal Scientist and Head of Functional Genomics at Wyeth Pharmaceuticals in Collegeville, PA, Senior scientist II at Open Biosystems/Thermo Fisher in Huntsville, AL., Dharmacon/ GE Healthcare in Lafayette, CO., and SomaGenics, Inc., in Santa Cruz, CA.
He won several awards (a doctoral fellowship from NATO (North Atlantic Treaty Organization), Young Investigator Award at the Symposium on RNA Biology III, Pfizer Excellence Awards for contributions towards Biomarkers of Lupus Disease Study).
Dr. Seyhan did his postdoctoral fellowship with Professor Bernard Grandchamp and Carol Beaumont at Xavier Bichat Hospital, the University of Paris VII studying ferritin gene regulation during erythroid differentiation/proliferation on a postdoctoral fellowship from the National Institute of Health and Medical Research of France (INSERM). He did another fellowship with Professor John Burke at the University of Vermont studying hairpin ribozyme biochemistry and their use as RNA therapeutics.
Dr. Seyhan earned his Ph.D. in Biological Sciences from Michigan Technological University (MTU), Houghton, MI on a NATO (North Atlantic Treaty Organization) Science Fellowship and BS degree in Biology from Hacettepe University, Ankara Turkey.
| Strandberg, Jillian, Louie, Anna, Lee, Seulki, Hahn, Marina, Srinivasan, Praveen, George, Andrew, De La Cruz, Arielle, Zhang, Leiqing, Hernandez Borrero, Liz, Huntington, Kelsey E., De La Cruz, Payton, Seyhan, Attila A., Koffer, Paul P., Wazer, David E., DiPetrillo, Thomas A., Graff, Stephanie L., Azzoli, Christopher G., Rounds, Sharon I., Klein-Szanto, Andres J., Tavora, Fabio, Yakirevich, Evgeny, Abbas, Abbas E., Zhou, Lanlan, El-Deiry, Wafik S. "TRAIL agonists rescue mice from radiation-induced lung, skin or esophageal injury." Journal of Clinical Investigation, 2025. |
| Seyhan, Attila A. "Circulating Liquid Biopsy Biomarkers in Glioblastoma: Advances and Challenges." International Journal of Molecular Sciences, vol. 25, no. 14, 2024, pp. 7974. |
| Zhou, Lanlan, Zhang, Leiqing, Zhang, Jun, Wu, Laura Jinxuan, Zhang, Shengliang, George, Andrew, Hahn, Marina, Safran, Howard P., Chen, Clark C., Seyhan, Attila A., Wong, Eric T., El-Deiry, Wafik S. "Combination of Imipridone ONC201 or ONC206 with Temozolomide and Radiotherapy in triple ITR therapy reduces intracranial tumor burden and prolongs survival in an orthotopic wild-type IDH GBM mouse model." 2024. |
| Almhanna, Khaldoun, Breakstone, Rimini, Raufi, Alexander, Wood, Roxanne, Webber, Amy, Dionson, Sopha, Cavanagh, Lindsay, Seyhan, Attila A., Safran, Howard, El-Deiry, Wafik. "Nivolumab plus ONC201 plus in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) patients: a Brown University Oncology Research Group phase Ib/II study (BrUOG379)." Translational Gastroenterology and Hepatology, vol. 9, 2024, pp. 15-15. |
| Seyhan, Attila A., Carini, Claudio. "Precision medicine: success stories and challenges from science to implementation." The New Era of Precision Medicine, 2024, pp. 83-113. |
| Wu, Laura Jinxuan. "Synergistic combination therapy with ONC201 or ONC206, and enzalutamide or darolutamide in preclinical studies of castration-resistant prostate cancer." American Journal of Cancer Research, vol. 14, no. 12, 2024, pp. 6012-6036. |
| Wu, Laura, Pinho-Schwermann, Maximilian, Zhou, Lanlan, Zhang, Leiqing, Huntington, Kelsey E., Malpass, Ryan, Seyhan, Attila A., Carneiro, Benedito A., El-Deiry, Wafik S. "Synergistic combination therapy with ONC201 or ONC206, Enzalutamide and Darolutamide in preclinical studies of castration-resistant prostate cancer." [], 2024. |
| Tian, Xiaobing, Srinivasan, Praveen R., Tajiknia, Vida, Sanchez Sevilla Uruchurtu, Ashley F., Seyhan, Attila A., Carneiro, Benedito A., De La Cruz, Arielle, Pinho-Schwermann, Maximilian, George, Andrew, Zhao, Shuai, Strandberg, Jillian, Di Cristofano, Francesca, Zhang, Shengliang, Zhou, Lanlan, Raufi, Alexander G., Navaraj, Arunasalam, Zhang, Yiqun, Verovkina, Nataliia, Ghandali, Maryam, Ryspayeva, Dinara, El-Deiry, Wafik S. "Targeting apoptotic pathways for cancer therapy." Journal of Clinical Investigation, vol. 134, no. 14, 2024. |
| Seyhan, Attila A. "Trials and Tribulations of MicroRNA Therapeutics." International Journal of Molecular Sciences, vol. 25, no. 3, 2024, pp. 1469. |
| Carini, Claudio, Seyhan, Attila A. "Tribulations and future opportunities for artificial intelligence in precision medicine." Journal of Translational Medicine, vol. 22, no. 1, 2024. |
| Raufi AG, May MS, Hadfield MJ, Seyhan AA, El-Deiry WS. "Advances in Liquid Biopsy Technology and Implications for Pancreatic Cancer." International Journal of Molecular Sciences, vol. 24, no. 4, 2023. |
| El-Deiry, Wafik S., Graff, Stephanie L., Azzoli, Christopher G., Dizon, Don S., Fenton, Mary Anne, Sikov, William M., Safran, Howard, Khan, Hina, Khurshid, Humera, Schumacher, Andrew, Zhou, Lanlan, Zhao, Shuai, Seyhan, Attila A., Ryspayeva, Dinara, Wood, Roxanne, Winer, Arthur, Calleja, Elizabeth Martine, Ross, Eric A. "BrUOG 387: Phase Ib investigator-initiated trial of a heat shock protein 90 inhibitor (HSP90i) combined with a CDK4/6i in advanced breast cancer progressing on CDK4/6i and in solid tumors with retinoblastoma (Rb)-deficiency (IND163592)." Journal of Clinical Oncology, vol. 41, no. 16_suppl, 2023, pp. TPS3167-TPS3167. |
| Seyhan, Attila A. "Circulating microRNAs as Potential Biomarkers in Pancreatic Cancer—Advances and Challenges." International Journal of Molecular Sciences, vol. 24, no. 17, 2023, pp. 13340. |
| Attila A. Seyhan, Claudio Carini. "Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates." International Journal of Molecular Sciences, vol. 24, no. 41, 2023, pp. 1-34. |
| Di Cristofano, Francesca, George, Andrew, Tajiknia, Vida, Ghandali, Maryam, Wu, Laura, Zhang, Yiqun, Srinivasan, Praveen, Strandberg, Jillian, Hahn, Marina, Sanchez Sevilla Uruchurtu, Ashley, Seyhan, Attila A., Carneiro, Benedito A., Zhou, Lanlan, Huntington, Kelsey E., El-Deiry, Wafik S. "Therapeutic targeting of TRAIL death receptors." Biochemical Society Transactions, 2023. |
| Di Cristofano F, George A, Tajiknia V, Ghandali M, Wu L, Zhang Y, Srinivasan P, Strandberg J, Hahn M, Sanchez Sevilla Uruchurtu A, Seyhan AA, Carneiro BA, Zhou L, Huntington KE, El-Deiry WS. "Therapeutic targeting of TRAIL death receptors." Biochemical Society transactions, 2023. |
| Strandberg, Jillian, Louie, Anna, Lee, Seulki, Hahn, Marina, Srinivasan, Praveen, George, Andrew, De La Cruz, Arielle, Zhang, Leiqing, Borrero, Liz Hernandez, Huntington, Kelsey E., De La Cruz, Payton, Seyhan, Attila A., Koffer, Paul P., Wazer, David E., DiPetrillo, Thomas A., Azzoli, Christopher G., Rounds, Sharon I., Graff, Stephanie L., Abbas, Abbas E., Zhou, Lanlan, El-Deiry, Wafik S. "TRAIL agonists rescue mice from radiation-induced lung injury." biorxiv, 2023. |
| Zhang, Shengliang, Huntington, Kelsey E., Zhou, Lanlan, Seyhan, Attila A., Kun, Bianca, Carneiro, Benedito A., Kreiling, Jill, Sedivy, John M., El-Deiry, Wafik S. "TRAIL pathway suppression of cancer cell growth and immune cell-mediated tumor cell-killing in a senescent fibroblast-constructed tumor microenvironment." biorxiv, 2023. |
| Seyhan, Attila A. "Trials and Tribulations of MicroRNA Therapeutics." [], 2023. |
| Zhang, Shengliang, Carlsen, Lindsey, Hernandez Borrero, Liz, Seyhan, Attila A., Tian, Xiaobing, El-Deiry, Wafik S. "Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer." [], 2022. |
| Zhang, Shengliang, Carlsen, Lindsey, Hernandez Borrero, Liz, Seyhan, Attila A., Tian, Xiaobing, El-Deiry, Wafik S. "Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer." Biomolecules, vol. 12, no. 4, 2022, pp. 548. |
| Huntington KE, Louie A, Zhou L, Seyhan AA, Maxwell AW, El-Deiry WS. "Colorectal cancer extracellular acidosis decreases immune cell killing and is partially ameliorated by pH-modulating agents that modify tumor cell cytokine profiles." American journal of cancer research, vol. 12, no. 1, 2022, pp. 138-151. |
| Seyhan, Attila A. "The Current State of Precision Medicine and Targeted-Cancer Therapies: Where Are We?.", 2022, pp. 119-200. |
|
Kelsey E Huntington,
Anna Louie,
Lanlan Zhou,
Attila A Seyhan,
Aaron WP Maxwell,
Wafik S El-Deiry.
"Colorectal cancer extracellular
acidosis decreases immune cell killing
and is partially ameliorated by pH-modulating
agents that modify tumor cell cytokine profiles." Am J Cancer Res, 2021.
|
| Zhang, Yiqun, Zhou, Lanlan, Safran, Howard, Borsuk, Robyn, Lulla, Rishi, Tapinos, Nikos, Seyhan, Attila A., El-Deiry, Wafik S. "EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG." Neoplasia, vol. 23, no. 8, 2021, pp. 792-810. |
| Tian, Xiaobing, Zhang, Shengliang, Zhou, Lanlan, Seyhan, Attila A., Hernandez Borrero, Liz, Zhang, Yiqun, El-Deiry, Wafik S. "Frontiers in Pharmacology." Frontiers in Pharmacology, vol. 12, no. 2621, 2021. |
| Ilyas Sahin, I., Andrew George, and Attila A. Seyhan. "Therapeutic Targeting of Alternative RNA Splicing in Gastrointestinal Malignancies and Other Cancers." International Journal of Molecular Sciences, vol. 22, no. 21, 2021, pp. 11790. |
| Sahin I, George A, Seyhan AA. "Therapeutic Targeting of Alternative RNA Splicing in Gastrointestinal Malignancies and Other Cancers." International Journal of Molecular Sciences, vol. 22, no. 21, 2021. |
| Raufi,Alexander G. Liguori,Nicholas R. Carlsen,Lindsey Parker,Cassandra Hernandez Borrero,Liz Zhang,Shengliang Tian,Xiaobing Louie,Anna Zhou,Lanlan Seyhan,Attila A. El-Deiry,Wafik S. "Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma." Frontiers in Pharmacology, vol. 12, no. 3166, 2021, pp. 751568. |
| Chang, Wen-I, Zhou, Lanlan, Seyhan, Attila A., Zhang, Yiqun, El-Deiry, Wafik S. "Abstract 3902: Novel therapeutic targeting of epigenetic aberrations in pediatric sarcomas through combination of ONC201 and HDAC inhibitors." Tumor Biology, 2020. |
| Zhang, Yiqun, Zhou, Lanlan, Glantz, Michael, Safran, Howard, Seyhan, Attila, El-Deiry, Wafik S. "Abstract 4042: Potent synergistic tumor cell suppression from combination of ONC201 and epigenetic modulators EZH2 or HDAC inhibitors provides a novel treatment strategy for solid tumors." Experimental and Molecular Therapeutics, 2020. |
| Zhou, Lanlan, Huntington, Kelsey, Zhang, Shengliang, Carlsen, Lindsey, So, Eui-Young, Parker, Cassandra, Sahin, Ilyas, Safran, Howard, Kamle, Suchitra, Lee, Chang-Min, Geun Lee, Chun, A. Elias, Jack, S. Campbell, Kerry, T. Naik, Mandar, J. Atwood, Walter, Youssef, Emile, A. Pachter, Jonathan, Navaraj, Arunasalam, A. Seyhan, Attila, Liang, Olin, S. El-Deiry, Wafik. "MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection." Oncotarget, vol. 11, no. 46, 2020, pp. 4201-4223. |
| Seyhan AA, Gregory B, Cribbs AP, Bhalara S, Li Y, Loreth C, Zhang Y, Guo Y, Lin LL, Feldmann M, Williams LM, Brennan FM, Taylor PC. "Novel biomarkers of a peripheral blood interferon signature associated with drug-naïve early arthritis patients distinguish persistent from self-limiting disease course." Scientific reports, vol. 10, no. 1, 2020, pp. 8830. |
| Prabhu VV, Morrow S, Rahman Kawakibi A, Zhou L, Ralff M, Ray J, Jhaveri A, Ferrarini I, Lee Y, Parker C, Zhang Y, Borsuk R, Chang WI, Honeyman JN, Tavora F, Carneiro B, Raufi A, Huntington K, Carlsen L, Louie A, Safran H, Seyhan AA, Tarapore RS, Schalop L, Stogniew M, Allen JE, Oster W, El-Deiry WS. "ONC201 and imipridones: Anti-cancer compounds with clinical efficacy." Neoplasia, vol. 22, no. 12, 2020, pp. 725-744. |
| Zhang, Yiqun, Zhou, Lanlan, Zhang, Shengliang, Borsuk, Robyn, Safran, Howard P., Seyhan, Attila A., El-Deiry, Wafik S. "Abstract LB-C10: Preclinical synergistic anti-tumor effect against multiple cancer types by EZH2 inhibitor EPZ-6438 plus imipridone ONC201 to mimic H3K27M mutation observed in DIPG tumors that respond to ONC201 in the clinic." Therapeutic Agents: Other, 2019. |
| Seyhan, Attila A., Carini, Claudio. "Are innovation and new technologies in precision medicine paving a new era in patients centric care?." Journal of Translational Medicine, vol. 17, no. 1, 2019. |
|
Claudio Carini, Attila A. Seyhan, Mark D. Fidock, Alain J. van Gool.
"Definitions and Conceptual Framework of Biomarkers in Precision Medicine." Handbook of Biomarkers and Precision Medicine, edited by Claudio Carini, Mark D. Fidock, Alain J. van Gool, Chapman and Hall/CRC, 2019, pp. 6.
|
| Seyhan, Attila A. "Lost in translation: the valley of death across preclinical and clinical divide – identification of problems and overcoming obstacles." Translational Medicine Communications, vol. 4, no. 1, 2019. |
| Nunez Lopez YO, Retnakaran R, Zinman B, Pratley RE, Seyhan AA. "Predicting and understanding the response to short-term intensive insulin therapy in people with early type 2 diabetes." Molecular Metabolism, vol. 20, 2019, pp. 63-78. |
| Nunez Lopez YO, Garufi G, Pasarica M, Seyhan AA. "Elevated and Correlated Expressions of miR-24, miR-30d, miR-146a, and SFRP-4 in Human Abdominal Adipose Tissue Play a Role in Adiposity and Insulin Resistance." International Journal of Endocrinology, vol. 2018, 2018, pp. 1-7. |
| Nunez Lopez YO, Pittas AG, Pratley RE, Seyhan AA. "Circulating levels of miR-7, miR-152 and miR-192 respond to vitamin D supplementation in adults with prediabetes and correlate with improvements in glycemic control." The Journal of nutritional biochemistry, vol. 49, 2017, pp. 117-122. |
| Nunez Lopez YO, Coen PM, Goodpaster BH, Seyhan AA. "Gastric bypass surgery with exercise alters plasma microRNAs that predict improvements in cardiometabolic risk." International Journal of Obesity, vol. 41, no. 7, 2017, pp. 1121-1130. |
| Pachori AS, Madan M, Nunez Lopez YO, Yi F, Meyer C, Seyhan AA. "Reduced skeletal muscle secreted frizzled-related protein 3 is associated with inflammation and insulin resistance." Obesity, vol. 25, no. 4, 2017, pp. 697-703. |
| Seyhan AA. "A multiplexed miRNA and transgene expression platform for simultaneous repression and expression of protein coding sequences." Molecular bioSystems, vol. 12, no. 1, 2016, pp. 295-312. |
| Nunez Lopez YO, Garufi G, Seyhan AA. "Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes." Molecular bioSystems, vol. 13, no. 1, 2016, pp. 106-121. |
|
Attila Seyhan, Claudio Carini.
"From isolation to integration: a systems biology approach for the discovery of therapeutic targets and biomarkers." Biosimilar Clinical development: scientific considerations and new methodologies, edited by Kerry B. Barker, Sandeep M. Menon, Ralph B. D'Agostino, Sr., Siyan Xu, Bo Jin, PhD, 2016.
|
|
Candida Fratazzi, Attila Seyhan, Claudio Carini.
"Immunogenicity of Biological Products: Current Perspectives and Future Implications." Biosimilar Clinical Development: Scientific Considerations and New Methodologies, CRC Press, 2016.
|
| Seyhan AA, Nunez Lopez YO, Xie H, Yi F, Mathews C, Pasarica M, Pratley RE. "Pancreas-enriched miRNAs are altered in the circulation of subjects with diabetes: a pilot cross-sectional study." Scientific Reports, vol. 6, no. 1, 2016, pp. 31479. |
| Garufi G, Seyhan AA, Pasarica M. "Elevated secreted frizzled-related protein 4 in obesity: a potential role in adipose tissue dysfunction." Obesity, vol. 23, no. 1, 2015, pp. 24-7. |
| Seyhan AA. "microRNAs with different functions and roles in disease development and as potential biomarkers of diabetes: progress and challenges." Molecular BioSystems, vol. 11, no. 5, 2015, pp. 1217-1234. |
|
Claudio Carini, Attila A. Seyhan.
"Biomarkers for drug development: the time is now." Clinical and Statistical Considerations in Personalized Medicine, edited by Claudio Carini, Sandeep M Menon, Mark Chang, Chapman and Hall/CRC, 2014.
|
|
Attila Seyhan, Claudio Carini.
"RNAi Screens: Triumphs and Tribulations." Clinical and Statistical Considerations in Personalized Medicine, edited by Claudio Carini, Sandeep M Menon, Mark Chang, CRC Press, 2014.
|
| Seyhan, A., O'Toole, M., Zhang, Y., Immermann, F.W., Hill, A., Reddy, P., Masferrer, J., Zhou, T., Mounts, W., Whitley, M., Walker, T., Kamp, S., James, J., Sridharan, S., Merrill, J.T., Honczarenko, M. "OP0063 Impact of baseline interferon pathway activation on widespread gene expression changes with disease flare in lupus patients: Interim report from the bold (biomarkers of lupus disease) study:." Annals of the Rheumatic Diseases, vol. 71, no. Suppl 3, 2013, pp. 74.2-74. |
| Seyhan AA, Varadarajan U, Choe S, Liu W, Ryan TE. "A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers." Molecular bioSystems, vol. 8, no. 5, 2012, pp. 1553-70. |
| Seyhan AA, Varadarajan U, Choe S, Liu Y, McGraw J, Woods M, Murray S, Eckert A, Liu W, Ryan TE. "A genome-wide RNAi screen identifies novel targets of neratinib sensitivity leading to neratinib and paclitaxel combination drug treatments." Molecular bioSystems, vol. 7, no. 6, 2011, pp. 1974-89. |
| Seyhan AA. "RNAi: a potential new class of therapeutic for human genetic disease." Human Genetics, vol. 130, no. 5, 2011, pp. 583-605. |
| Attila A. Seyhan. "Biomarkers in drug discovery and development." European Pharmaceutical Review, no. 5, 2010, pp. 19-25. |
| Seyhan AA, Rya TE. "RNAi screening for the discovery of novel modulators of human disease." Current pharmaceutical biotechnology, vol. 11, no. 7, 2010, pp. 735-56. |
| Attila A. Seyhan. "RNAi screens for the identification and validation of novel targets: Current status and challenges." European Pharmaceutical Review, no. 6, 2010, pp. 13-24. |
| Seyhan AA, Alizadeh BN, Lundstrom K, Johnston BH. "RNA interference-mediated inhibition of Semliki Forest virus replication in mammalian cells." Oligonucleotides, vol. 17, no. 4, 2007, pp. 473-84. |
| Vlassov AV, Korba B, Farrar K, Mukerjee S, Seyhan AA, Ilves H, Kaspar RL, Leake D, Kazakov SA, Johnston BH. "shRNAs targeting hepatitis C: effects of sequence and structural features, and comparision with siRNA." Oligonucleotides, vol. 17, no. 2, 2007, pp. 223-36. |
| Seyhan AA. "Generation of Ribozymes by Rolling Circle Transcription of Promoterless Single-Stranded DNA Circles in Mammalian Cells." Turk biyokimya dergisi = Turkish journal of biochemistry, vol. 31, no. 1, 2006, pp. 2-12. |
| Ilves H, Kaspar RL, Wang Q, Seyhan AA, Vlassov AV, Contag CH, Leake D, Johnston BH. "Inhibition of hepatitis C IRES-mediated gene expression by small hairpin RNAs in human hepatocytes and mice." Annals of the New York Academy of Sciences, vol. 1082, 2006, pp. 52-5. |
| Seyhan AA, Vlassov AV, Johnston BH. "RNA interference from multimeric shRNAs generated by rolling circle transcription." Oligonucleotides, vol. 16, no. 4, 2006, pp. 353-63. |
| Seyhan AA, Vlassov AV, Ilves H, Egry L, Kaspar RL, Kazakov SA, Johnston BH. "Complete, gene-specific siRNA libraries: production and expression in mammalian cells." RNA, vol. 11, no. 5, 2005, pp. 837-46. |
| Seyhan AA, Vitiello D, Shields MT, Burke JM. "Ribozyme inhibition of alphavirus replication." Journal of Biological Chemistry, vol. 277, no. 29, 2002, pp. 25957-62. |
| Seyhan AA, Burke JM. "Mg2+-independent hairpin ribozyme catalysis in hydrated RNA films." RNA, vol. 6, no. 2, 2000, pp. 189-98. |
| Seyhan AA, Amaral J, Burke JM. "Intracellular RNA cleavage by the hairpin ribozyme." Nucleic acids research, vol. 26, no. 15, 1998, pp. 3494-504. |
| Murray JB, Seyhan AA, Walter NG, Burke JM, Scott WG. "The hammerhead, hairpin and VS ribozymes are catalytically proficient in monovalent cations alone." Chemistry & Biology, vol. 5, no. 10, 1998, pp. 587-95. |
| Beaumont C, Jones R, Seyhan A, Grandchamp B. "A hemin-inducible enhancer lies 4.5 Kb upstream of the mouse ferritin H subunit gene." Systems Biology of RNA Binding Proteins, vol. 356, 1994, pp. 211-8. |
| Beaumont C, Seyhan A, Yachou AK, Grandchamp B, Jones R. "Mouse ferritin H subunit gene. Functional analysis of the promoter and identification of an upstream regulatory element active in erythroid cells." Journal of Biological Chemistry, vol. 269, no. 32, 1994, pp. 20281-8. |
A molecular biologist by training, Dr. Seyhan has over 20 years of experience in multidisciplinary areas including molecular biology and particularly RNA biology, circulating miRNA biomarkers, and RNA-based therapeutics (ribozymes, RNAi, miRNAs), oncology, immunology, and autoimmune diseases, metabolic diseases, and diabetes, and virology in academia, industry, and biotech sectors in leading roles with project and people management skills.
He possesses experience in Translational research, biomarker, target, and drug development strategy design, functional genomics, RNA-therapeutics, technical management, team, and partnership building, quality assurance, and project management, and the ability to liaise with cross-functional teams and external partners.
He is experienced in all phases of preclinical and clinical (Phase I – II) protocol development, including management of trial goals, timelines, data acquisition, analysis, interpretation, authorship of documents, budget management, and overall trial oversight, in adherence with guidelines (e.g. GLP, GCP), corporate SOPs and policies.
During his industry roles, he helped to establish the Functional Genomics group at Wyeth to support translational and biomarker efforts across various disease areas and later the Translational Research Department in the Inflammation & Immunology Therapeutic Unit of Pfizer.
Following his postdoctoral research on the generation and application of combinatorial libraries of RNA therapeutics, his research in biotech led to the development of targeted and combinatorial RNA therapeutics targeting the same or multiple RNA targets for HCV, HIV, alphaviruses, dengue virus, and TNF-alpha for rheumatoid arthritis. This body of work resulted in several patents, successful research funds from NIH and DOD, and potential novel RNA-based therapies that can be highly specific and sensitive and can target pharmacologically non-druggable targets. He served as the primary investigator or co-investigator in all of these studies.
Based on his previous research in biotech on the design and generation of pathway targeted or genome-wide lentiviral RNAi (shRNA and miRNA) libraries, his line of research in the pharmaceutical industry led to the identification of novel drug targets, pathways, combination treatment strategies (i.e. which led to neratinib and paclitaxel combination treatments in phase II trials), and drug-resistant and patient selection biomarkers. The biomarkers identified from this study hold promise for understanding how some patients resist chemotherapy while others respond to those therapies.
As PI in academia, he conducted translational research in diabetes at the Translational Res. Inst. for Metabolism & Diabetes, Florida Hospital and at Sanford Burnham Prebys Medical Discovery Institute, Orlando, FL.
As PI or co-Investigator on several NIH-or industry-funded grants, he produced several peer-reviewed publications from each project on the discovery and development of patient-derived tissue and liquid biopsy miRNA and protein biomarkers in autoimmune diseases and diabetes.
His current research is focused on mechanisms of therapy resistance with efforts in novel combination drug therapy by targeting glioblastoma and other solid tumors through epigenetic and other cancer-relevant pathways.
| Year | Degree | Institution |
|---|---|---|
| 1993 | PhD | Michigan TechnologicalUniversity |
| 1986 | BS | Hacettepe University |
| Postdoctoral Fellow | University of Vermont, College of Medicine, Department of Microbiology and Molecular Genetics | 1995-1999 | Burlington, VT, United States |
| Postdoctoral Fellow | University of Paris, Faculte de Medecine Xavier Bichat, Laboratoire de Genetique Moleculaire | 1993-1995 | Paris, France |
1988-1991 A three-year NATO Science Fellowship Program awarded by the Scientific and Technical Research Council of Turkey to pursue a Ph.D. program in the area of Biotechnology.
1991-1992 A one-year doctoral fellowship awarded by the Department of Biological Sciences, Michigan Technological University.
1991 Received a NATO (North Atlantic Treaty Organization) grant and a Michigan Technological University Graduate Student Council travel grant to participate in the NATO-Advanced Studies Institute conference entitled "Recent Advances in Industrial Applications of Biotechnology", September 16-27, 1991, Kusadasi, Turkey.
1991-1992 A summer term fellowship awarded by the Dean of Graduate School, Michigan Technological University, 1991-1992.
1991-1992 A two-year postdoctoral fellowship funded by National Institute of Health and Medical Research of France (Institut National de la Santé et de la Recherche Médicale [INSERM]), 1993-1995.
1996 Invited role model speaker at a pre-college youth program at Michigan Technological University, Houghton, MI 49931, USA; designed to introduce young people to opportunities in Engineering, Math, and Science, June 24-25, 1996.
1995-1999 A four-year postdoctoral fellowship funded by NIH (National Institute of Health)
1999 Young Investigator Award. Symposium on RNA Biology III, RNA: Tool and Target, October 15-17, 1999, North Caroline Biotechnology Center, Research Triangle Park, NC.
2000 2000 CalTIP Award, The Bay Area Regional Technology Alliance (California Technology Innovation Project. "A systematic, universal method for developing improved gene inhibitors". Funded ($ 150,000). Co-Principal investigator (Co-PI).
2009-2012 Wyeth / Pfizer 2009 – 2012 Long-Term Incentive Plan Award.
2013 Pfizer Excellence Awards for contributions towards Biomarkers of Lupus Disease Study (BOLD) March 07, 2013.
2014 Florida Hospital Graduate Medical Education, Certificate of appreciation. (GME Scholars & Quality Improvement Day-Oral and Poster Presentation Judging). 2014 GME Research and Quality Improvement Day. May 20, 2014.
| Director of Translational Oncology Operations / Assoc. Professor (Adj. Research). 2019- |
| Director of Translational Medicine Operations/Associate Professor (Research). Fox Chase Cancer Center, 2018-2019 |
| Associate Professor. Florida Hospital, 2013-2017 |
| Research Affiliate. MIT, 2013-2017 |
| Associate Professor (Adj). Sanford Burnham Prebys Medical Discovery Institute, 2013-2017 |
| Senior Principal Scientist. Pfizer, 2010-2012 |
| Head of Functional Genomics / Principal Scientist. Wyeth Pharmaceuticals, 2008-2010 |
